ALBUQUERQUE, N.M., Sept. 27 /PRNewswire/ -- VeraLight, Inc., a privately held medical device company, based here, today announced the appointment of Ms. Mirasol G. Panlilio as vice president of marketing and sales. Ms. Panlilio will be a key member of the company’s management team, responsible for strategic marketing and sales of VeraLight’s Scout DS(TM) non-invasive diabetes screening system, currently under development.
“Ms. Panlilio brings to VeraLight an exceptional track record of creative leadership in global product marketing and clinical community relations for many successful diabetes products,” said David Van Avermaete, CEO of VeraLight. “Her extensive experience will be an invaluable asset as we move our lead product through clinical trials and market introduction.”
Ms. Panlilio has nearly 20 years of life science industry experience -- over 15 years at LifeScan, Inc. (a Johnson & Johnson company), and most recently at Abbott Diabetes Care. Prior to joining VeraLight, she served as director of worldwide strategic marketing of Abbott’s in vivo business, charged with developing and commercializing the FreeStyle Navigator(R) continuous glucose monitoring system. At LifeScan, she held various management positions in marketing and business development. She headed the marketing efforts of the company’s hospital business unit, championed its first joint product venture with Inverness Medical, and led the sales and marketing teams for its Asia Pacific business. Additionally, she managed the development and successful commercialization of several new products, including LifeScan’s best-selling OneTouch(R) blood glucose monitoring system.
About VeraLight
VeraLight, Inc., based in Albuquerque, New Mexico, is a privately held medical instrumentation company applying its proprietary Spectroscopic Advanced Glycation Endproduct (SAGE) detection technology to develop Scout DS -- the first non-invasive diabetes screening system that provides health care professionals with a more accurate and convenient method for detecting type 2 diabetes and pre-diabetes based on the presence of biomarkers found in skin. Weighing about 10 pounds, Scout DS is a simple-to-use device that does not require the patient to fast or provide a blood sample. Total measurement time is about a minute. For more information see http://www.veralight.com.
VeraLight, Inc.
CONTACT: David Van Avermaete, CEO of VeraLight, Inc., +1-925-895-5308,david.vanavermaete@veralight.com; or Charles Versaggi, Ph.D. of VersaggiBiocommunications(R), +1-415-806-6039, cv@versaggibio.com
Web site: http://www.veralight.com//
